Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

Experimental: Dose Level 1
SON-1010 Dose Level 1 + Atezolizumab

Biological: SON-1010
SON-1010 +/- Atezolizumab

Experimental: Dose Level 2
SON-1010 Dose Level 2 + Atezolizumab

Biological: SON-1010
SON-1010 +/- Atezolizumab

Experimental: Dose Level 3
SON-1010 Dose Level 3 + Atezolizumab

Biological: SON-1010
SON-1010 +/- Atezolizumab

Experimental: Dose Level 4
SON-1010 Dose Level 4 + Atezolizumab

Biological: SON-1010
SON-1010 +/- Atezolizumab

Experimental: Dose Level 5
SON-1010 Dose Level 5 + Atezolizumab

Biological: SON-1010
SON-1010 +/- Atezolizumab

Experimental: RP2D Expansion in Patients with Platinum-resistant Ovarian Cancer
RP2D Dose of SON-1010 + Atezolizumab

Biological: SON-1010
SON-1010 +/- Atezolizumab

Experimental: Randomized Arm #1 in Patients with Platinum-resistant Ovarian Cancer
SON-1010 @ RP2D Alone

Biological: SON-1010
SON-1010 +/- Atezolizumab

Experimental: Randomized Arm #2 in Patients with Platinum-resistant Ovarian Cancer
SON-1010 @ RP2D + Atezolizumab

Biological: SON-1010
SON-1010 +/- Atezolizumab

No Intervention: Randomized Arm #3 in Patients with Platinum-resistant Ovarian Cancer
Standard of Care

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 22, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments